# 3-O-Methyldopa

MedChemExpress

| Cat. No.:          | HY-113468A  |       |         |  |
|--------------------|---|-------|---------|--|
| CAS No.:           | 300-48-1  |       |         |  |
| Molecular Formula: | C <sub>10</sub> H <sub>13</sub> NO <sub>4</sub>               |       |         |  |
| Molecular Weight:  | 211.21  |       |         |  |
| Target:            | Dopamine Receptor; Endogenous Metabolite                      |       |         |  |
| Pathway:           | GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease |       |         |  |
| Storage:           | Powder  | -20°C | 3 years |  |
|                    |   | 4°C   | 2 years |  |
|                    | In solvent  | -80°C | 2 years |  |
|                    |   | -20°C | 1 vear  |  |

## SOLVENT & SOLUBILITY

| In Vitro                     | H <sub>2</sub> O : 16.67 mg/mL (78.93 mM; Need ultrasonic)                    |  |            |            |           |  |  |
|------------------------------|---|--|------------|------------|-----------|--|--|
| Preparing<br>Stock Solutions |   | Solvent Mass<br>Concentration                          | 1 mg       | 5 mg       | 10 mg     |  |  |
|                              | 1 mM  | 4.7346 mL  | 23.6731 mL | 47.3462 mL |           |  |  |
|                              |   | 5 mM   | 0.9469 mL  | 4.7346 mL  | 9.4692 mL |  |  |
|                              | 10 mM   | 0.4735 mL  | 2.3673 mL  | 4.7346 mL  |           |  |  |
|                              | Please refer to the solubility information to select the appropriate solvent. |  |            |            |           |  |  |
| In Vivo                      | 1. Add each solvent o<br>Solubility: 10 mg/i                                  | one by one: PBS<br>mL (47.35 mM); Clear solution; Need | ultrasonic |            |           |  |  |

| <b>BIOLOGICAL ACTIV</b> | ТТҮ   |
|-------------------------|---|
| Description             | 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT).<br>3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine <sup>[1]</sup> . |

#### REFERENCES

[1]. Masato Asanuma, et al. 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA. BMC Neurosci. 2016 Jul 25;17(1):52.

# **Product** Data Sheet

.Ο

HO

О

NH₂

ОH

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA